Table 3.

Factors associated with progression-free survival

Variable	Total (n)	Median PFS (mo)	Univariate HR (95% Cl)	Univariate p-value	Multivariate HR (95% CI)	Multivariate p-value
Age at tertiary surgery
<55 years	42	10.5	ref
≥55 years	72	17.4	0.87 (0.55-1.38)	0.56
Stage
I	10	13.2	ref
II	16	14.3	1.60 (0.60-4.29)	0.35
III	76	12.0	1.94 (0.82-4.59)	0.13
IV	12	17.4	2.23 (0.75-6.61)	0.15
Grade
Low grade	14	18.9	ref
High grade	100	12.0	0.50 (0.24-1.04)	0.06
Histology
Serous	86	11.3	ref
Endometrioid	10	11.1	0.52 (0.22-1.22)	0.13
Clear Cell	4	14.3	0.47 (0.12-1.93)	0.30
Carcinosarcoma	3	2.5	6.07 (1.83-20.12)	0.003*
Mucinous	5	-	0.20 (0.04-0.82)	0.03*
Other	2	8.5	0.59 (0.08-4.26)	0.60
Mixed	4	29.9	0.52 (0.16-1.65)	0.26
Serous
Non-serous	28	29.9	ref			0.007
Serous	86	11.3	1.94 (1.12-3.34)	0.02*	2.12 (1.22-3.68)
BRCA status
Negative	44	12.0	ref
Any BRCA	22	21.0	0.77 (0.40-1.47)	0.42
Initial cytoreduction
≤1 cm residual	92	12.0	ref
≥1 cm residual	9	8.1	1.27 (0.61-2.65)	0.53
Secondary cytoreduction
CGR	75	14.6	ref
Any residual	36	11.1	1.20 (0.75-1.91)	0.45
Time to first recurrence
<2 years	44	9.2	ref
≥2 years	64	19.7	0.54 (0.34-0.84)	0.006*
Treatment-free interval
≤1 year	40	8.2	ref			0.005
>1 year	73	17.4	0.51 (0.33-0.81)	0.004*	0.52 (0.33-0.82)
Time from secondary cytoreduction
<2 years	53	9.4	ref
≥2 years	61	23.7	0.51 (0.33-0.79)	0.003*
Platinum sensitivity
Sensitive	101	15.0	ref			0.002
Resistant	13	7.7	2.76 (1.45-5.28)	0.002*	2.80 (1.46-5.38)
CA-125 prior to tertiary cytoreduction (continuous)			1.000 (1.000-1.001)	0.27
Residual disease at tertiary
CGR	102	13.3	ref
Any residual	12	11.1	1.61 (0.82-3.16)	0.17
Sites of recurrence
Single	51	20.9	ref
Multiple	63	11.1	1.29 (0.83-2.01)	0.25
Cytotoxic therapy after tertiary cytoreduction
Cytotoxic	72	14.3	ref
No cytotoxic	12	10.2	1.01 (0.64-1.58)	0.98

PFS, progression-free survival; CGR, complete gross resection

^*statistically significant